Carl June

C-Path's Translational Therapeutics Accelerator proudly announced today a $250,000 grant award to Peter Wipf, Ph.D., a distinguished researcher and professor at the University of Pittsburgh and his colleagues Dr. Zhou Wang UPMC Chair in Urological Research and Dr. Joel B. Nelson, the Frederic N. Schwentker Professor and Chairman of the Department of Urology. This funding will support their pioneering research aimed at developing a novel small-molecule drug to combat castration-resistant prostate cancer. Prostate cancer is the second leading cause of cancer-related deaths in people assigned male at birth in the United States, claiming over 30,000 lives annually. While first line therapy is effective initially, many patients experience relapse due to the reactivation of the androgen receptor (AR). Drs. Nelson, Wang and Wipf’s innovative approach targets a particular constitutively active variant of AR that plays an important role in this reactivated state drug-resistant relapse. “C-Path’s TRxA is committed to funding research that addresses significant medical challenges, and Drs. Nelson, Wang and Wipf’s project epitomizes this mission,” said TRxA Executive Director Maaike Everts, Ph.D. “We are enthusiastic about the potential impact of this research on the treatment of CRPC and the improvement of patient outcomes. Importantly, this highly collaborative program combines medicinal chemistry, cancer biology, and the translational and clinical expertise to drive this project to clinical solutions for the patients.” Full details, here: https://lnkd.in/dxZaQs8D #CPath #TRxA #UniversityofPittsburgh #translational #therapeutic #prostatecancer #datasharing #druddiscovery #drugdevelopment #urology #collaboration

15

2 Comments

Does the addition of the anti-PD-1 antibody serplulimab and anti-VEGF HLX04 (a bevacizumab biosimilar) to XELOX chemotherapy improve progression-free survival in metastatic colorectal cancer? Read the Viewpoint and results of the phase 2 part of the ASTRUM-015 clinical trial, both published in Med by Cell Press. #colorectalcancer #immunotherapy #antiPD1 #antiVEGF #XELOX #PFS #clinicaltrial #ASTRUM015 https://lnkd.in/ePKf9GqC

4

Blocking IL-12 or IL-23 for Crohn’s disease? Read this interesting paper

2

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 "𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐏𝐫𝐨𝐦𝐢𝐬𝐞 𝐨𝐟 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬" The article highlights personalized cancer vaccines, focusing on Dr. Catherine Wu's work at Dana-Farber Cancer Institute. Vaccines like 𝐍𝐞𝐨𝐕𝐚𝐱 train the immune system to target neoantigens, proteins unique to cancer cells. Early trials, especially in melanoma, show promise, particularly when combined with immunotherapies. Research is expanding to other cancers, including glioblastoma and ovarian cancer, with efforts to 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬 using prediction algorithms, new adjuvants, and delivery methods. Despite challenges, this field shows 𝐠𝐫𝐞𝐚𝐭 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐟𝐨𝐫 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭. To read the full article, check the comments section. #Neoantigens #PersonalizedMedicine #VaccineDevelopment #IntavisPeptideNews

11

3 Comments